Asset Management One Co. Ltd. Trims Stock Holdings in Hologic, Inc. $HOLX

Asset Management One Co. Ltd. reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 4.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,820 shares of the medical equipment provider’s stock after selling 7,352 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Hologic were worth $9,371,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in HOLX. Victory Capital Management Inc. lifted its position in shares of Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock valued at $408,283,000 after acquiring an additional 1,692,177 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Hologic by 473.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after acquiring an additional 1,405,085 shares in the last quarter. Nuance Investments LLC lifted its position in shares of Hologic by 623.7% in the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after acquiring an additional 931,920 shares in the last quarter. Invesco Ltd. lifted its position in shares of Hologic by 18.8% in the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after acquiring an additional 764,573 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Hologic in the first quarter valued at $30,317,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Hologic stock opened at $73.95 on Tuesday. The stock’s 50-day moving average is $67.78 and its 200-day moving average is $64.13. The company has a market cap of $16.45 billion, a price-to-earnings ratio of 30.68, a price-to-earnings-growth ratio of 2.54 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on HOLX shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Hologic in a research report on Wednesday, October 8th. Leerink Partners increased their target price on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 21st. UBS Group increased their target price on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Finally, BTIG Research reiterated a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $79.23.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.